Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- Ann: Race releases complete cardio-protection data & video
Yes to an extent as the price that will ultimately be able to be...
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.68 |
Change
0.130(8.39%) |
Mkt cap ! $277.8M |
Open | High | Low | Value | Volume |
$1.65 | $1.75 | $1.61 | $652.3K | 389.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 201 | $1.68 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.69 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1201 | 1.680 |
2 | 9754 | 1.655 |
1 | 3048 | 1.650 |
2 | 311 | 1.640 |
1 | 1100 | 1.635 |
Price($) | Vol. | No. |
---|---|---|
1.690 | 1000 | 1 |
1.700 | 24635 | 5 |
1.710 | 7000 | 1 |
1.720 | 6110 | 2 |
1.740 | 3030 | 1 |
Last trade - 15.52pm 14/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.67 |
  |
Change
0.130 ( 8.61 %) |
|||
Open | High | Low | Volume | ||
$1.64 | $1.73 | $1.63 | 33428 | ||
Last updated 15.54pm 14/05/2024 ? |
Featured News
RAC (ASX) Chart |